骨質疏鬆症與代謝性骨質疾病：全球市場（2010∼2025年） 是由出版商Visiongain在2010年04月所出版的。
這份英文市場調查報告書包含121 Pages 價格從美金2331起跳。
代謝性骨質疾病全球市場收入在2009年達到120億美金。由於高齡化與診斷技術的進步，全球罹病率增加，骨質疏鬆症及其他代謝性骨質疾病患者數，在2020年預估將超過4億人。
本報告書在介紹代謝性骨質疾病概要的同時，與全球市場動向與地區市場概要、到2025年的市場增加預測等內容交織而成，整理摘記其概要如下。
第一章 實施概要
第二章 代謝性骨質疾病：原因、診斷、治療
- 骨頭是活組織
- 代謝性骨質疾病
- 代謝性骨質疾病之治療
第三章 全球代謝性骨質疾病市場：2010年∼2025年
- 該市場自2010年開始擴大
- 骨質疏鬆症獨佔目前的代謝性骨質疾病市場
- 雙磷酸鹽類藥物居2009年該市場之領先地位
- 雙磷酸鹽類藥物在2010年∼2025年間市佔率將逐漸流失
- 該市場主要業界參與企業
- 該市場主要品牌
- 2009年代謝性骨質疾病市場認證
第四章 代謝性骨質疾病市場之SWOT分析
第五章 代謝性骨質疾病市場之地區概況：2010∼2025年
- 北美洲領導2009年市場
- 主要國別市場：2009年
- 主要國家市場預測：2010年∼2025年
- 中國與印度在2010∼2025年間將有最大的成長幅度
第六章 藥物開發線上
第七章 骨頭疾病相關專家專訪
第八章 結論
圖表
Abstract
Report Details
-how will aging populations, improved diagnosis and new treatments benefit this market?
The bone metabolism treatments market generated pharmaceutical revenues of
over $12 bn worldwide in 2009. The incidence and prevalence of bone metabolism
disorders are on the rise worldwide, in line with an ageing population and
improvements in diagnosis. The increasing number of older people offers
significant commercial and therapeutic opportunities. The number of
osteoporosis and other bone metabolism patients may exceed 400 million by
2020, reports suggest. Governments and other healthcare providers are
investing in health education, diagnosis and treatments for those chronic,
debilitating - but controllable - disorders, as our new report discusses.
As Osteoporosis & Bone Metabolism Disorders: World Market 2010-2025 shows,
this field is important therapeutically and commercially. Which segments of
the bone metabolism disorders market will grow fastest in years to come? How
will the osteoporosis market cope with patent expiry? What are the therapeutic
and commercial trends to watch? How will national markets perform from 2010 to
2025? What will happen to the current leading products and drug classes? Our
report covers those and other questions, providing the information that you
need.
We predict that the global market for bone metabolism disorder drugs will
expand from 2010 onwards, driven by increasing prevalence of disorders among a
rising population of older people worldwide. National markets for those
products will expand at different rates, as will different treatment forms.
The market will depend upon products with superior performance for its
success. Our new report shows how technologies that increase clinical
effectiveness, safety and ease of use will be important therapeutically and
commercially for bone disorders, benefiting stakeholders.
Detailed analysis of the global bone metabolism disorders market
Osteoporosis & Bone Metabolism Disorders: World Market 2010-2025 examines that
sector through a comprehensive review of information sources. We harness both
primary and secondary research. This report provides unique sales forecasts,
market share analyses, discussions of the R&D pipeline and analyses of
commercial drivers and restraints, including a SWOT analysis.
There are over 50 tables and figures included, as well as three full
interviews with experts - these are totally unique and unavailable anywhere
else. The result is a comprehensive market- and industry-centred study, with
detailed analyses and informed opinion to benefit your work.
Why you should buy Osteoporosis & Bone Metabolism Disorders: World Market 2010-2025
This report gives you the following benefits in particular:
- You will receive a comprehensive analysis of the prospects for bone
metabolism disorder drugs from 2010 to 2025, including predicted revenues,
growth rates and other data for leading products
- You will receive an overall sales forecast for that market area from 2010
to 2025, as well as that for main drug classes, with comprehensive discussions
and other supporting information
- You will find out where the market is heading - technologically and
commercially - from 2010 onwards
- You will receive sales forecasts for the leading national markets from
2010 to 2025 (US, Japan, France, Germany, UK, Spain, Italy, Canada, China and
India)
- You will identify R&D pipeline developments and up-and-coming products
- You will discover the drivers, restraints, competition and opportunities
influencing the bone metabolism disorders treatment sector
- You will investigate under-met needs in that market sector, with
therapeutic requirements and commercial opportunities discussed
- You will discover expert views from our survey, including full interview
transcripts.
Table of Contents
1. Executive Summary
- 1.1 Bone Metabolism Disorders: Market Review
- 1.2 Overview of Chapters in this Report
- 1.3 Research & Analysis Methods
2. Bone Metabolism Disorders: Causes, Effects, Diagnosis and Treatments
- 2.1 Bone is a Living Tissue
- 2.1.1 Bone Structure
- 2.1.2 Bone Remodelling
- 2.1.3 Regulation of Bone Remodelling
- 2.1.3.1 Factors Affecting Bone Metabolism
- 2.1.3.2 Parathyroid Hormone (PTH)
- 2.1.3.3 Calcitonin
- 2.1.3.4 Vitamin D/Calcitriol
- 2.1.3.5 Other Hormones
- 2.1.3.6 Local Cell Signalling Factors
- 2.1.3.7 Physical Stress
- 2.1.4 Bone Growth and Remodelling
- 2.2 Bone Metabolism Disorders
- 2.2.1 Osteoporosis
- 2.2.1.1 Osteoporosis Leads to Bone Fractures
- 2.2.1.2 Causes of Osteoporosis
- 2.2.1.3 Osteoporosis Risk Factors
- 2.2.1.4 Diagnosis of Osteoporosis
- 2.2.1.5 Osteoporosis Screening
- 2.2.1.6 Prevalence of Osteoporosis
- 2.2.1.7 Counting the Cost of Osteoporosis
- 2.2.2 Paget' s Disease of Bone
- 2.2.2.1 Paget' s Disease is a Chronic Skeletal Disorder
- 2.2.2.2 The Cause of Paget' s Disease
- 2.2.2.3 Diagnosis of Paget' s Disease
- 2.2.2.4 Prevalence of Paget' s Disease
- 2.2.3 Bone Metastases
- 2.2.4 Primary Hyperparathyroidism
- 2.2.5 Secondary Hyperparathyroidism and Renal Osteodystrophy
- 2.3 Treatment of Bone Metabolism Disorders
- 2.3.1 Bisphosphonates
- 2.3.2 Vitamin D or K Analogues
- 2.3.3 Selective Oestrogen-Receptor Modulators (SERMs)
- 2.3.4 Parathyroid Hormones (PTH)
- 2.3.5 Calcimimetics
- 2.3.6 Calcitonins
- 2.3.7 Strontium Compounds
- 2.3.8 Calcium and Vitamin D Supplements
3. The World Bone Metabolism Disorders Market, 2010-2025
- 3.1 The Bone Metabolism Drug Market Will Expand from 2010
- 3.2 Osteoporosis Dominates the Bone Metabolism Market Currently
- 3.3 Bisphosphonates Led the Bone Metabolism Market in 2009
- 3.4 Bisphosphonates Will Gradually Lose Market Share from 2010 to 2025
- 3.5 Key Industrial Players in the Bone Metabolism Market
- 3.6 Leading Brands in the Bone Metabolism Market: Forecasts and Discussions
- 3.6.1 The Top 15 Bone Metabolism Drugs in 2009
- 3.6.2 Actonel/Optinate Will Fall From Top Position
- 3.6.3 Zometa/Aclasta/Reclast: Sales Prospects
- 3.6.4 Bonviva/Boniva/Bondronat: Sales Prospects
- 3.6.5 Fosamax/Fosamax Plus D: Increasingly Impacted by Generic
Competition
- 3.6.6 Evista: Sales Peaked in 2008
- 3.6.7 Forteo/Forsteo: Sustained Growth for a Bone Anabolic Agent
- 3.6.8 Zemplar: Sales Prospects
- 3.6.9 Sensipar/Mimpara: Amgen' s Calcimimetic
- 3.6.10 Protelos: Sales Prospects
- 3.6.11 Hectorol: Sales Prospects
- 3.6.12 Teiroc/Bonalon: Sales Prospects
- 3.6.13 Benet: Sales Prospects
- 3.6.14 Miacalcin/Miacalcic: Sales Prospects
- 3.6.15 Elcitonin: Sales Prospects
- 3.6.16 Alfarol (Alfacalcidol, Chugai)
- 3.6.17 Preotact Has a Limited Market?
- 3.6.18 Generic Alendronate
- 3.7 Approvals in the Bone Metabolism Disorders Market in 2009
- 3.7.1 Fabyln (Lasofoxifene, Pfizer/Ligand)
- 3.7.2 Conbriza/Viviant (Bazedoxifene, Wyeth/Ligand)
4. SWOT Analysis of the Bone Metabolism Disorders Market
- 4.1 SWOT Analysis of the Market
- 4.2 Strengths of the Bone Metabolism Pharmaceutical Sector
- 4.3 Generic Competition is the Principal Challenge Facing the Bone
Metabolism Sector
- 4.4 Opportunities for the Bone Metabolism Disorders Market
- 4.5 Threats to the Bone Metabolism Disorders Market
- 4.5.1 Drug Side-Effect Publicity
- 4.5.2 Reimbursement for Bone Metabolism Drugs
5. Geographical Profile of the Bone Metabolism Market, 2010-2025
- 5.1 North America Led the Bone Metabolism Market in 2009
- 5.2 Leading Bone Metabolism Country Markets, 2009
- 5.3 Bone Metabolism Market Forecasts for Leading Countries, 2010-2025
- 5.4 China and India Will Have Highest Growth from 2010-2025
6. The Bone Metabolism Disorders R&D Pipeline
- 6.1 Strong Pipeline for Bone Metabolism Disorders
- 6.2 Reformulations and Novel Therapeutic Agents
- 6.2.1 Pipeline Developments to Improve Formulations
- 6.2.2 Bone Anabolic Agents in the Pipeline
- 6.3 RANKL Inhibitors and Cathepsin K Inhibitors
- 6.4 Key Pipeline Products: Registration Stage
- 6.4.1 Prolia (Denosumab/ AMG 162) (Amgen)
- 6.4.1.1 Prolia is an Effective Treatment for Osteoporosis and Bone
Metastases
- 6.4.1.2 Biologics Licence Application (BLA) for Prolia Submitted in
2009
- 6.4.1.3 Launch of Prolia Expected in H2 2010
- 6.4.2 Eldecalcitol (ED-71, Chugai)
- 6.5 Key Pipeline Products: Phase III
- 6.5.1 Odanacatib (MK 0822, Merck & Co)
- 6.5.2 EX101 Effervescent Alendronate (EffRx/Nycomed)
- 6.5.3 SM021 (Salmon Calcitonin, Novartis)
- 6.6 Key Pipeline Products: Phase II
- 6.6.1 JTT-305 (Japan Tobacco)
- 6.6.2 SAN-134 (Sanos Bioscience)
- 6.6.3 BA058 (PTHrP Analogue, Radius Health/Ipsen)
- 6.6.4 ONO-5334 (Ono)
- 6.6.5 BN003/CaPTHymone (Oral PTH, Bone Medical/Axcess)
- 6.6.6 ViaDerm -hPTH (PTH, TransPharma/Eli Lilly)
- 6.6.7 Strontium Malonate (Osteologix)
- 6.6.8 Capsitonin (Oral Calcitonin, Bone Medical)
- 6.6.9 AMG 785 (CDP-8581) (Amgen/UCB)
- 6.7 Key Pipeline Products: Phase I
- 6.7.1 ACE-011 (Acceleron Pharma)
7. Interviews with Experts on Bone Disorders
- 7.1 Interview with Dr Stuart Silverman, Medical Director of the
Osteoporosis Medical Center, OMC Clinical Research Center, CA, US
- 7.1.1 Unmet Needs in the Osteoporosis Market
- 7.1.2 New Bone Anabolic Agents
- 7.1.3 The Difficulties of Developing New Osteoporosis Drugs
- 7.1.4 Current Pipeline Drugs for Osteoporosis
- 7.1.5 Decline of Bisphosphonates
- 7.2 Interview with Dr Matthew Drake, Mayo Clinic, MN, US
- 7.2.1 Unmet Needs for Osteoporosis Patients
- 7.2.2 Future Bone Anabolic Agents
- 7.2.3 Potential in the Late-Stage Osteoporosis Pipeline
- 7.2.4 Intricacies of Developing New Osteoporosis Drugs
- 7.2.5 Side-Effects of Established Bone Metabolism Disorder Drugs
- 7.2.6 The Development of Drugs to Prevent Osteoporosis
- 7.2.7 Growth Opportunities in the Osteoporosis Market
- 7.3 Interview with Dr Jasbir Seehra, Chief Scientific Officer, Senior Vice
President and Founder, Acceleron Pharma, Inc., MA, US
- 7.3.1 Unmet Needs in Osteoporosis Patients
- 7.3.2 On ACE-011 Fulfilling Unmet Needs in the Market
- 7.3.3 On ACE-011 in Comparison With Current Therapies
- 7.3.4 Advantages and Disadvantages of ACE-011 Compared with Other
Pipeline Drugs
8. Conclusions
- 8.1 The Bone Metabolism Disorders Market 2010-2025 - What will the Future
Hold?
- 8.2 Growth Drivers for the Bone Metabolism Disorders Market
- 8.3 Closing Thoughts on the Industry and Market
List of Tables
- Table 2.1 Hormones Involved in Bone Metabolism
- Table 2.2 Worldwide Prevalence of Osteoporosis
- Table 2.3 Bone Metabolism Disorder Therapies, 2010
- Table 3.1 Bone Metabolism Disorders: World Pharmaceutical Sales, 2009-2025
- Table 3.2 Bone Metabolism Disorders: World Sales and Market Shares by
Disease Area, 2009
- Table 3.3 Bone Metabolism Disorders: World Sales and Market Shares by Drug
Class, 2009
- Table 3.4 Bisphosphonates: World Sales and Market Shares by Brand, 2009
- Table 3.5 Bone Metabolism Disorders: World Sales by Drug Class, 2009-2025
- Table 3.6 Bone Metabolism Disorders: World Sales and Market Shares by
Manufacturer, 2009
- Table 3.7 Leading Bone Metabolism Disorders Brands: World Sales, 2009
- Table 3.8 Leading Bone Metabolism Disorders Brands: World Sales, 2009-2025
- Table 3.9 Generic Alendronate Manufacturers, 2009
- Table 4.1 SWOT Chart for the Bone Metabolism Disorders Sector, 2010
- Table 4.2 Expected Patent Expiries in the Bone Metabolism Market
- Table 5.1 Bone Metabolism Disorders: World Sales and Market Shares by
Geographical Region, 2009
- Table 5.2 Leading Bone Metabolism Country Markets: Sales and Market
Shares, 2009
- Table 5.3 Leading Bone Metabolism Country Markets: Sales, 2009-2025
- Table 5.4 Population Aged 65 or Over: US, Japan, China and India, 2009-2025
- Table 6.1 Bone Metabolism Disorders: R&D Pipeline, 2010
- Table 6.2 Disadvantages of Current Anabolic Bone Agents, 2010
- Table 8.1 Leading Bone Metabolism Country Markets: World Market Shares,
2009 and 2025
List of Figures
- Figure 2.1 Appearance of Healthy Bone
- Figure 2.2 Bone Affected by Osteoporosis
- Figure 2.3 Bones Commonly Affected by Paget' s Disease
- Figure 3.1 Bone Metabolism Disorders: World Pharmaceutical Sales, 2009-2025
- Figure 3.2 Bone Metabolism Disorders: World Market Shares by Disease Area,
2009
- Figure 3.3 Bone Metabolism Disorders: World Market Shares by Drug Class,
2009
- Figure 3.4 Bisphosphonates: World Market Shares by Brand, 2009
- Figure 3.5 Bone Metabolism Disorders: World Sales by Drug Class, 2009-2025
- Figure 3.6 Bone Metabolism Disorders: World Market Shares by Drug Class,
2015
- Figure 3.7 Bone Metabolism Disorders: World Market Shares by Drug Class,
2020
- Figure 3.8 Bone Metabolism Disorders: World Market Shares by Drug Class,
2025
- Figure 3.9 Bone Metabolism Disorders: World Market Shares by Manufacturer,
2009
- Figure 3.10 Leading Bone Metabolism Disorders Brands, 2009
- Figure 3.11 Actonel/Optinate: World Sales, 2009-2025
- Figure 3.12 Leading Bone Metabolism Brands (Bisphosphonates): World Sales,
2009-2025
- Figure 3.13 Zometa/Aclasta/Reclast: World Sales, 2009-2025
- Figure 3.14 Bonviva/Boniva/Bondronat: World Sales, 2009-2025
- Figure 3.15 Fosamax/Fosamax Plus D: World Sales, 2009-2025
- Figure 3.16 Leading Bone Metabolism Brands (Non-Bisphosphonates): World
Sales, 2009-2025
- Figure 3.17 Evista: World Sales, 2009-2025
- Figure 3.18 Forteo/Forsteo: World Sales, 2009-2025
- Figure 3.19 Zemplar: World Sales, 2009-2025
- Figure 3.20 Sensipar/Mimpara: World Sales, 2009-2025
- Figure 3.21 Protelos: World Sales, 2009-2025
- Figure 3.22 Hectorol: World Sales, 2009-2025
- Figure 5.1 Bone Metabolism Disorders: World Market Shares by Geographical
Region, 2009
- Figure 5.2 Bone Metabolism Disorders: World Market Shares for Leading
Countries, 2009
- Figure 5.3 Leading Bone Metabolism Country Markets (Higher Group): Sales,
2009-2025
- Figure 5.4 Leading Bone Metabolism Country Markets (Lower Group): Sales,
2009-2025
- Figure 5.5 Bone Metabolism Disorders: World Market Shares for Leading
Countries, 2015
- Figure 5.6 Bone Metabolism Disorders: World Market Shares for Leading
Countries, 2020
- Figure 5.7 Bone Metabolism Disorders: World Market Shares for Leading
Countries, 2025
- Figure 8.1 Bone Metabolism Disorders: World Sales, 2009-2025
Companies Listed
- Abbott Laboratories
- Abiogen Pharma
- Acceleron Pharma
- American College of Physicians
- Amgen
- Apotex
- Asahi Kasei Pharma
- Astellas Pharma
- Axxess Pharma
- Banyu (subsidiary of Merck & Co.)
- Barr Pharmaceuticals
- Bayer HealthCare
- Bone Care International
- Bone Medical
- British Geriatrics Society
- British Orthopaedic Association
- Cedars-Sinai Medical Center, CA, US
- Celgene Corporation
- Chugai Pharmaceutical Co (part of Roche Group)
- Cytochroma
- Daiichi Sankyo
- Dr. Reddy' s Laboratories
- EffRx
- Eisai
- Eli Lilly
- Emisphere Technologies
- Esteve
- European Medicines Agency(EMEA)
- Food and Drug Administration (FDA)
- Genzyme
- Green Cross Corporation
- GlaxoSmithKline (GSK)
- International Osteoporosis Foundation (IOF)
- Ipsen
- Japan Tobacco
- Kirin Brewery
- Leo Pharma
- Ligand Pharmaceuticals
- Mayo Clinic, MN, US
- Merck & Co.
- Nordic Bioscience
- Novartis
- Novo Nordisk
- NPS Pharmaceuticals
- Nycomed
- OMC Clinical Research Center, CA, US
- Ono Pharmaceutical
- Osteologix
- Pfizer
- Preventive Services Task Force (USPSTF)
- Proctor & Gamble
- Proteolix
- Radius Health
- Ratiopharm
- Roche
- Sandoz (Novartis)
- Sanofi-Aventis
- Sanos Bioscience
- Schering-Plough
- Servier
- Shanghai Huadong University
- Shire
- Sigma (Australia)
- STADA Pharmaceuticals
- Taisho Pharmaceutical
- Takeda Pharmaceutical Company Limited
- Teijin Pharma
- Teva Pharmaceutical Industries
- The American College of Physicians
- TransPharma
- UCB Pharma
- Unigene Laboratories
- University of California (UCLA), CA, US
- Upsher-Smith Laboratories
- Watson Pharmaceuticals
- World Health Organization (WHO)
- Wyeth (now part of Pfizer)
- Zelos Therapeutics
|
